- Published on
Ophthalmology – Anophthalmia
Anophthalmia is a rare congenital condition characterized by the complete absence of the globe. It must be carefully distinguished from severe microphthalmia, in which small remnants of ocular tissue may still be present but are only detectable with imaging or histologic evaluation. The condition may occur in isolation or as part of a broader systemic or syndromic disorder. It can affect one eye (unilateral) or both eyes (bilateral), with significant implications for visual development and overall prognosis.
The condition has an estimated incidence of approximately 10–19 per 100,000 newborns. Risk factors include chromosomal abnormalities, congenital syndromes, and intrauterine exposures to teratogenic agents such as radiation, alcohol, thalidomide, retinoic acid, hydantoin, and certain drugs like lysergic acid diethylamide. Although genetic factors are implicated, no single gene defect has been identified as specifically responsible for true anophthalmia. Preventive strategies include prenatal ultrasound screening and avoidance of teratogenic exposures during pregnancy.
Pathophysiologically, anophthalmia results from complete failure of development of the primary optic vesicle during embryogenesis. The etiology may be genetic, environmental, or idiopathic. The condition is often associated with other abnormalities, including midline craniofacial defects and, in some cases, significant developmental delay, particularly when part of a chromosomal or syndromic disorder.
Clinically, patients present with absence of the globe and reduced orbital volume, often resulting in an enophthalmic appearance and small palpebral fissures. Eyelids may appear normal, small, or partially fused, while adnexal structures such as eyelashes, tarsal glands, and the lacrimal system are usually present. A thorough systemic examination is essential to identify associated anomalies, particularly involving the brain and craniofacial structures. Examination of the parents may help differentiate true anophthalmia from severe microphthalmia, especially if features such as coloboma are identified in family members.
Diagnosis is supported by imaging studies such as MRI or CT scans, which confirm the absence of ocular tissue, optic nerve, and extraocular muscles. In cases with associated anomalies, genetic testing including karyotyping or microarray analysis may be indicated. Serial imaging may also be useful in monitoring orbital bone development over time.
The differential diagnosis includes severe microphthalmia, cystic eye, acquired anophthalmia due to trauma or surgery, phthisis bulbi following severe ocular disease, and rare conditions such as cyclopia or synophthalmia. Distinguishing between these entities is important for prognosis and management.
Management is primarily supportive and focuses on promoting normal orbital and facial development, as well as optimizing cosmetic outcomes. In unilateral cases, protection of the remaining functional eye with safety glasses is essential. The use of a scleral shell or conformer helps stimulate growth of the orbit and surrounding tissues. In more severe cases, surgical interventions such as placement of progressively enlarging orbital expanders, dermal fat grafts, or intraorbital balloons may be required to support orbital development.
Long-term care involves regular follow-up with an ocularist to adjust prostheses and monitor orbital growth, especially during the first five years of life when development is most rapid. Monitoring of developmental milestones and school performance is also important, particularly in children with associated systemic abnormalities. Referral to genetic counseling and support services for visual impairment is recommended.
The prognosis varies widely and depends largely on the presence and severity of associated systemic anomalies. Isolated unilateral anophthalmia may have a relatively good functional outcome with appropriate management, whereas bilateral cases or those associated with significant neurologic or systemic abnormalities often carry a more guarded prognosis.
Anophthalmia is a rare congenital condition characterized by the complete absence of the globe. It must be carefully distinguished from severe microphthalmia, in which small remnants of ocular tissue may still be present but are only detectable with imaging or histologic evaluation. The condition may occur in isolation or as part of a broader systemic or syndromic disorder. It can affect one eye (unilateral) or both eyes (bilateral), with significant implications for visual development and overall prognosis.
The condition has an estimated incidence of approximately 10–19 per 100,000 newborns. Risk factors include chromosomal abnormalities, congenital syndromes, and intrauterine exposures to teratogenic agents such as radiation, alcohol, thalidomide, retinoic acid, hydantoin, and certain drugs like lysergic acid diethylamide. Although genetic factors are implicated, no single gene defect has been identified as specifically responsible for true anophthalmia. Preventive strategies include prenatal ultrasound screening and avoidance of teratogenic exposures during pregnancy.
Pathophysiologically, anophthalmia results from complete failure of development of the primary optic vesicle during embryogenesis. The etiology may be genetic, environmental, or idiopathic. The condition is often associated with other abnormalities, including midline craniofacial defects and, in some cases, significant developmental delay, particularly when part of a chromosomal or syndromic disorder.
Clinically, patients present with absence of the globe and reduced orbital volume, often resulting in an enophthalmic appearance and small palpebral fissures. Eyelids may appear normal, small, or partially fused, while adnexal structures such as eyelashes, tarsal glands, and the lacrimal system are usually present. A thorough systemic examination is essential to identify associated anomalies, particularly involving the brain and craniofacial structures. Examination of the parents may help differentiate true anophthalmia from severe microphthalmia, especially if features such as coloboma are identified in family members.
Diagnosis is supported by imaging studies such as MRI or CT scans, which confirm the absence of ocular tissue, optic nerve, and extraocular muscles. In cases with associated anomalies, genetic testing including karyotyping or microarray analysis may be indicated. Serial imaging may also be useful in monitoring orbital bone development over time.
The differential diagnosis includes severe microphthalmia, cystic eye, acquired anophthalmia due to trauma or surgery, phthisis bulbi following severe ocular disease, and rare conditions such as cyclopia or synophthalmia. Distinguishing between these entities is important for prognosis and management.
Management is primarily supportive and focuses on promoting normal orbital and facial development, as well as optimizing cosmetic outcomes. In unilateral cases, protection of the remaining functional eye with safety glasses is essential. The use of a scleral shell or conformer helps stimulate growth of the orbit and surrounding tissues. In more severe cases, surgical interventions such as placement of progressively enlarging orbital expanders, dermal fat grafts, or intraorbital balloons may be required to support orbital development.
Long-term care involves regular follow-up with an ocularist to adjust prostheses and monitor orbital growth, especially during the first five years of life when development is most rapid. Monitoring of developmental milestones and school performance is also important, particularly in children with associated systemic abnormalities. Referral to genetic counseling and support services for visual impairment is recommended.
The prognosis varies widely and depends largely on the presence and severity of associated systemic anomalies. Isolated unilateral anophthalmia may have a relatively good functional outcome with appropriate management, whereas bilateral cases or those associated with significant neurologic or systemic abnormalities often carry a more guarded prognosis.
- Published on
Ophthalmology – Anisometropia
Anisometropia is defined as a difference in refractive error between the two eyes and is one of the most common causes of amblyopia. It becomes particularly amblyogenic when the interocular difference exceeds certain thresholds, such as more than 1.50 diopters of hyperopia, more than 1.00 diopter of astigmatism, or more than 6.00 diopters of myopia. Two main forms are recognized: spherical equivalent anisometropia and astigmatic anisometropia. Because of unequal image clarity between the eyes, the brain preferentially uses the clearer image, leading to suppression of the blurrier eye and impaired visual development.
Anisometropia is relatively common, with a prevalence ranging from 1% to 11% of the population. Among affected individuals, approximately 25–60% develop amblyopia. The condition may change during childhood, but larger degrees of anisometropia, particularly greater than 3 diopters, are more likely to persist. Early detection is critical, as the risk of amblyopia increases with age if untreated, with a significant proportion of young children with anisometropia developing amblyopia over time.
Risk factors include prematurity, especially in association with retinopathy of prematurity, as well as congenital conditions such as ptosis, coloboma, cataract, congenital glaucoma, and microphthalmia. Any condition that leads to asymmetric visual input between the eyes in early life can predispose to anisometropia. Although there is no clear inheritance pattern, a family history increases risk, often reflecting the inheritance of underlying ocular conditions rather than anisometropia itself.
The underlying pathophysiology involves unequal visual input to the brain, which disrupts normal binocular visual development. This imbalance leads to suppression of the image from the more defocused eye and reduced stimulation of the corresponding neurons in the visual cortex. Over time, this results in amblyopia, characterized by decreased visual acuity that cannot be explained by structural abnormalities alone. Functional imaging studies have demonstrated reduced activation in the visual cortex and lateral geniculate nucleus corresponding to the amblyopic eye.
Clinically, anisometropia may present with unequal refractive prescriptions between the eyes or unilateral visual impairment. In some cases, it is detected during routine screening, particularly in children who may not report symptoms. A thorough eye examination is essential, including measurement of visual acuity and a complete dilated examination to exclude other causes of reduced vision. Cycloplegic refraction is critical for accurately identifying the degree of refractive difference between the eyes. Reduced contrast sensitivity may also be observed in anisometropic amblyopia.
The differential diagnosis includes any ocular or neurologic condition that can cause unilateral or asymmetric visual impairment, such as retinal disease, optic nerve pathology, or cortical visual disorders. It is also important to consider structural causes of refractive asymmetry, including differences in axial length, corneal curvature, or lens power.
Management focuses on correcting the refractive error and preventing or treating amblyopia. Spectacle correction is the first-line treatment and may alone lead to significant improvement in visual acuity, with many patients showing improvement over several months. In cases where amblyopia persists, additional therapy is required, typically involving occlusion (patching) of the better-seeing eye or pharmacologic penalization with atropine. Both approaches aim to stimulate use of the amblyopic eye and promote visual development. Contact lenses may be preferred in cases of high anisometropia to reduce image size differences (aniseikonia) and improve cosmetic acceptance.
Follow-up is essential to monitor visual improvement and ensure compliance with treatment. Younger children require more frequent monitoring due to the rapid changes in visual development and the risk of amblyopia. Care must also be taken to avoid occlusion amblyopia in the treated eye. Referral for surgical intervention may be necessary if an underlying structural cause such as cataract or ptosis is identified.
The prognosis is generally good with early detection and appropriate treatment. Many patients experience significant improvement in visual acuity with spectacles alone, and further gains can be achieved with amblyopia therapy. However, delayed treatment reduces the likelihood of full recovery, emphasizing the importance of early screening and intervention. Potential complications include persistent amblyopia and, less commonly, iatrogenic visual loss in the better eye due to overtreatment.
Anisometropia is defined as a difference in refractive error between the two eyes and is one of the most common causes of amblyopia. It becomes particularly amblyogenic when the interocular difference exceeds certain thresholds, such as more than 1.50 diopters of hyperopia, more than 1.00 diopter of astigmatism, or more than 6.00 diopters of myopia. Two main forms are recognized: spherical equivalent anisometropia and astigmatic anisometropia. Because of unequal image clarity between the eyes, the brain preferentially uses the clearer image, leading to suppression of the blurrier eye and impaired visual development.
Anisometropia is relatively common, with a prevalence ranging from 1% to 11% of the population. Among affected individuals, approximately 25–60% develop amblyopia. The condition may change during childhood, but larger degrees of anisometropia, particularly greater than 3 diopters, are more likely to persist. Early detection is critical, as the risk of amblyopia increases with age if untreated, with a significant proportion of young children with anisometropia developing amblyopia over time.
Risk factors include prematurity, especially in association with retinopathy of prematurity, as well as congenital conditions such as ptosis, coloboma, cataract, congenital glaucoma, and microphthalmia. Any condition that leads to asymmetric visual input between the eyes in early life can predispose to anisometropia. Although there is no clear inheritance pattern, a family history increases risk, often reflecting the inheritance of underlying ocular conditions rather than anisometropia itself.
The underlying pathophysiology involves unequal visual input to the brain, which disrupts normal binocular visual development. This imbalance leads to suppression of the image from the more defocused eye and reduced stimulation of the corresponding neurons in the visual cortex. Over time, this results in amblyopia, characterized by decreased visual acuity that cannot be explained by structural abnormalities alone. Functional imaging studies have demonstrated reduced activation in the visual cortex and lateral geniculate nucleus corresponding to the amblyopic eye.
Clinically, anisometropia may present with unequal refractive prescriptions between the eyes or unilateral visual impairment. In some cases, it is detected during routine screening, particularly in children who may not report symptoms. A thorough eye examination is essential, including measurement of visual acuity and a complete dilated examination to exclude other causes of reduced vision. Cycloplegic refraction is critical for accurately identifying the degree of refractive difference between the eyes. Reduced contrast sensitivity may also be observed in anisometropic amblyopia.
The differential diagnosis includes any ocular or neurologic condition that can cause unilateral or asymmetric visual impairment, such as retinal disease, optic nerve pathology, or cortical visual disorders. It is also important to consider structural causes of refractive asymmetry, including differences in axial length, corneal curvature, or lens power.
Management focuses on correcting the refractive error and preventing or treating amblyopia. Spectacle correction is the first-line treatment and may alone lead to significant improvement in visual acuity, with many patients showing improvement over several months. In cases where amblyopia persists, additional therapy is required, typically involving occlusion (patching) of the better-seeing eye or pharmacologic penalization with atropine. Both approaches aim to stimulate use of the amblyopic eye and promote visual development. Contact lenses may be preferred in cases of high anisometropia to reduce image size differences (aniseikonia) and improve cosmetic acceptance.
Follow-up is essential to monitor visual improvement and ensure compliance with treatment. Younger children require more frequent monitoring due to the rapid changes in visual development and the risk of amblyopia. Care must also be taken to avoid occlusion amblyopia in the treated eye. Referral for surgical intervention may be necessary if an underlying structural cause such as cataract or ptosis is identified.
The prognosis is generally good with early detection and appropriate treatment. Many patients experience significant improvement in visual acuity with spectacles alone, and further gains can be achieved with amblyopia therapy. However, delayed treatment reduces the likelihood of full recovery, emphasizing the importance of early screening and intervention. Potential complications include persistent amblyopia and, less commonly, iatrogenic visual loss in the better eye due to overtreatment.
- Published on
Ophthalmology – Anisocoria in Children
Anisocoria in children refers to a difference in pupil size of 0.5 mm or more between the two eyes. It is relatively common, with physiologic anisocoria accounting for the majority of cases and occurring in approximately 15–30% of the population. In these benign cases, there is no associated ocular or neurologic abnormality. However, anisocoria in children can occasionally indicate underlying pathology, making careful evaluation essential.
The causes of anisocoria range from benign physiologic variation to serious neurologic or ocular disease. Physiologic anisocoria is idiopathic and not associated with any risk factors. Other causes include trauma (ocular or systemic), inflammation such as iritis, meningitis, pharmacologic exposure to mydriatic or miotic agents, and congenital or acquired neurologic conditions. One particularly important cause is Horner syndrome, which may be congenital due to birth trauma or acquired due to neoplasms such as neuroblastoma. Third cranial nerve palsy, whether congenital or acquired, is another critical cause and may result from trauma, infection, tumors, or, rarely in children, aneurysms. Less common causes include Adie’s tonic pupil, pharmacologic dilation, traumatic iris damage, posterior synechiae, and anterior segment dysgenesis.
Pathophysiologically, anisocoria results from dysfunction or imbalance in the pupillary sphincter or dilator muscles, mechanical restriction of the iris, or disruption of the autonomic innervation to the pupil. In some cases, such as physiologic anisocoria, no structural or functional abnormality is identified.
A detailed history is essential in evaluation. Important aspects include the age of onset, duration, history of trauma (including birth trauma), prior surgeries, and associated symptoms such as ptosis, anhidrosis, or facial flushing. Reviewing old photographs can help determine whether the anisocoria is congenital or acquired. Symptoms such as ptosis or abnormal sweating may suggest Horner syndrome, while diplopia or abnormal eye movements may indicate third nerve palsy.
On physical examination, visual acuity is typically normal in physiologic anisocoria but may be reduced in conditions like third nerve palsy or Adie’s pupil due to amblyopia or accommodative dysfunction. Careful pupil examination is crucial. If anisocoria is greater in darkness, the smaller pupil is abnormal, suggesting conditions such as Horner syndrome or physiologic anisocoria. If anisocoria is greater in light, the larger pupil is abnormal, indicating possibilities such as third nerve palsy, Adie’s pupil, traumatic mydriasis, or pharmacologic dilation. Additional findings such as dilation lag, light-near dissociation, segmental iris constriction, iris heterochromia, and eyelid abnormalities can further aid diagnosis. Extraocular motility should also be assessed, as abnormalities may indicate third nerve involvement. A systemic examination, including palpation for masses in the abdomen or neck, is important when a neoplastic cause is suspected.
Diagnostic testing depends on the suspected underlying cause. In suspected Horner syndrome without clear birth trauma, urine testing for vanillylmandelic acid (VMA) and homovanillic acid (HVA) may be performed to screen for neuroblastoma, although imaging is often more sensitive. MRI of the brain, neck, chest, and abdomen is typically recommended when Horner syndrome is suspected. If third nerve palsy is suspected, MRI with magnetic resonance angiography may be indicated. Pharmacologic testing can also aid diagnosis: apraclonidine or cocaine drops for Horner syndrome, hydroxyamphetamine to localize the lesion, and dilute pilocarpine for Adie’s tonic pupil.
Management focuses on identifying and treating the underlying cause rather than the anisocoria itself. Physiologic anisocoria requires no treatment. In Adie’s tonic pupil, dilute pilocarpine may be used to improve symptoms and cosmesis. Posterior synechiae due to iritis may be treated with mydriatic agents and anti-inflammatory therapy. Amblyopia, which may occur in conditions like third nerve palsy or Adie’s pupil, should be managed with refractive correction, patching, or atropine penalization. Cosmetic contact lenses may be considered in older children if appearance is a concern. Urgent referral is required if a neoplasm is suspected, and infants with Adie’s pupil should be evaluated by pediatric neurology to exclude systemic disorders.
Follow-up depends on the underlying cause. Physiologic anisocoria does not require ongoing monitoring. Children with third nerve palsy or Adie’s pupil should be followed to monitor for amblyopia. Suspected but unconfirmed Horner syndrome may require reassessment and repeat testing after several months. Conditions such as anterior segment dysgenesis require monitoring for complications like glaucoma.
The prognosis is excellent for physiologic anisocoria, with no impact on vision or development. For other causes, the outcome depends on the underlying condition. Early identification is critical, particularly in cases associated with serious conditions such as neuroblastoma, where prompt diagnosis can be life-saving.
Anisocoria in children refers to a difference in pupil size of 0.5 mm or more between the two eyes. It is relatively common, with physiologic anisocoria accounting for the majority of cases and occurring in approximately 15–30% of the population. In these benign cases, there is no associated ocular or neurologic abnormality. However, anisocoria in children can occasionally indicate underlying pathology, making careful evaluation essential.
The causes of anisocoria range from benign physiologic variation to serious neurologic or ocular disease. Physiologic anisocoria is idiopathic and not associated with any risk factors. Other causes include trauma (ocular or systemic), inflammation such as iritis, meningitis, pharmacologic exposure to mydriatic or miotic agents, and congenital or acquired neurologic conditions. One particularly important cause is Horner syndrome, which may be congenital due to birth trauma or acquired due to neoplasms such as neuroblastoma. Third cranial nerve palsy, whether congenital or acquired, is another critical cause and may result from trauma, infection, tumors, or, rarely in children, aneurysms. Less common causes include Adie’s tonic pupil, pharmacologic dilation, traumatic iris damage, posterior synechiae, and anterior segment dysgenesis.
Pathophysiologically, anisocoria results from dysfunction or imbalance in the pupillary sphincter or dilator muscles, mechanical restriction of the iris, or disruption of the autonomic innervation to the pupil. In some cases, such as physiologic anisocoria, no structural or functional abnormality is identified.
A detailed history is essential in evaluation. Important aspects include the age of onset, duration, history of trauma (including birth trauma), prior surgeries, and associated symptoms such as ptosis, anhidrosis, or facial flushing. Reviewing old photographs can help determine whether the anisocoria is congenital or acquired. Symptoms such as ptosis or abnormal sweating may suggest Horner syndrome, while diplopia or abnormal eye movements may indicate third nerve palsy.
On physical examination, visual acuity is typically normal in physiologic anisocoria but may be reduced in conditions like third nerve palsy or Adie’s pupil due to amblyopia or accommodative dysfunction. Careful pupil examination is crucial. If anisocoria is greater in darkness, the smaller pupil is abnormal, suggesting conditions such as Horner syndrome or physiologic anisocoria. If anisocoria is greater in light, the larger pupil is abnormal, indicating possibilities such as third nerve palsy, Adie’s pupil, traumatic mydriasis, or pharmacologic dilation. Additional findings such as dilation lag, light-near dissociation, segmental iris constriction, iris heterochromia, and eyelid abnormalities can further aid diagnosis. Extraocular motility should also be assessed, as abnormalities may indicate third nerve involvement. A systemic examination, including palpation for masses in the abdomen or neck, is important when a neoplastic cause is suspected.
Diagnostic testing depends on the suspected underlying cause. In suspected Horner syndrome without clear birth trauma, urine testing for vanillylmandelic acid (VMA) and homovanillic acid (HVA) may be performed to screen for neuroblastoma, although imaging is often more sensitive. MRI of the brain, neck, chest, and abdomen is typically recommended when Horner syndrome is suspected. If third nerve palsy is suspected, MRI with magnetic resonance angiography may be indicated. Pharmacologic testing can also aid diagnosis: apraclonidine or cocaine drops for Horner syndrome, hydroxyamphetamine to localize the lesion, and dilute pilocarpine for Adie’s tonic pupil.
Management focuses on identifying and treating the underlying cause rather than the anisocoria itself. Physiologic anisocoria requires no treatment. In Adie’s tonic pupil, dilute pilocarpine may be used to improve symptoms and cosmesis. Posterior synechiae due to iritis may be treated with mydriatic agents and anti-inflammatory therapy. Amblyopia, which may occur in conditions like third nerve palsy or Adie’s pupil, should be managed with refractive correction, patching, or atropine penalization. Cosmetic contact lenses may be considered in older children if appearance is a concern. Urgent referral is required if a neoplasm is suspected, and infants with Adie’s pupil should be evaluated by pediatric neurology to exclude systemic disorders.
Follow-up depends on the underlying cause. Physiologic anisocoria does not require ongoing monitoring. Children with third nerve palsy or Adie’s pupil should be followed to monitor for amblyopia. Suspected but unconfirmed Horner syndrome may require reassessment and repeat testing after several months. Conditions such as anterior segment dysgenesis require monitoring for complications like glaucoma.
The prognosis is excellent for physiologic anisocoria, with no impact on vision or development. For other causes, the outcome depends on the underlying condition. Early identification is critical, particularly in cases associated with serious conditions such as neuroblastoma, where prompt diagnosis can be life-saving.
- Published on
Ophthalmology – Acute Multifocal Placoid Pigment Epitheliopathy (AMPPE)
Acute multifocal placoid pigment epitheliopathy (AMPPE) is a rare, acquired inflammatory disorder affecting the retinal pigment epithelium (RPE) and choroid. It typically presents with multiple yellowish-white placoid lesions at the level of the RPE, most often involving the posterior pole and macula. The condition is frequently bilateral, and lesions are often seen in different stages of evolution, with healing characterized by areas of RPE hyperplasia. AMPPE is generally considered a self-limited condition, although it can occasionally be associated with systemic complications.
The exact incidence is unknown due to its rarity. Some genetic associations have been reported, particularly with HLA-B7 and HLA-DR2, suggesting a possible immunologic predisposition. The underlying pathophysiology is thought to involve choroidal vascular compromise, leading to secondary ischemia and inflammation of the RPE. Although the precise etiology remains unclear, approximately one-third of patients report a preceding viral-like illness, supporting the possibility of an immune-mediated or post-infectious mechanism.
Patients typically present with sudden, painless visual loss, which may affect one or both eyes. Visual symptoms can include blurred vision or scotomas. On funduscopic examination, characteristic findings include multiple, flat, yellowish-white lesions at the level of the RPE and choroid, often located in the macular region. These lesions may appear in various stages, with some resolving while others are newly forming. As lesions heal, they leave behind areas of pigmentary change due to RPE alteration.
Fluorescein angiography is helpful in confirming the diagnosis, demonstrating early hypofluorescence of the lesions due to blockage or nonperfusion, followed by late hyperfluorescence as dye leaks into the affected areas. The differential diagnosis includes other inflammatory and infectious chorioretinal diseases such as serpiginous choroiditis, ampiginous chorioretinitis, ocular toxoplasmosis, sarcoidosis, ocular lymphoma, and Vogt-Koyanagi-Harada disease.
Management is typically conservative, as most cases resolve spontaneously without treatment within several weeks. Visual recovery usually occurs over 3 to 4 weeks. In cases where the fovea is involved and vision is significantly affected, a short course of systemic corticosteroids may be considered, although evidence supporting this approach is limited. Patients should be referred to a retinal specialist for confirmation of diagnosis and monitoring.
Close follow-up is important to ensure resolution and to monitor for rare complications. Recurrence is uncommon, and repeated episodes should prompt reconsideration of the diagnosis. A critical but rare complication is cerebral vasculitis, which can be life-threatening; therefore, any associated neurological symptoms such as altered mental status require urgent neurological evaluation. The prognosis is generally favorable, with most patients regaining good visual acuity unless significant RPE damage occurs in the foveal region.
Acute multifocal placoid pigment epitheliopathy (AMPPE) is a rare, acquired inflammatory disorder affecting the retinal pigment epithelium (RPE) and choroid. It typically presents with multiple yellowish-white placoid lesions at the level of the RPE, most often involving the posterior pole and macula. The condition is frequently bilateral, and lesions are often seen in different stages of evolution, with healing characterized by areas of RPE hyperplasia. AMPPE is generally considered a self-limited condition, although it can occasionally be associated with systemic complications.
The exact incidence is unknown due to its rarity. Some genetic associations have been reported, particularly with HLA-B7 and HLA-DR2, suggesting a possible immunologic predisposition. The underlying pathophysiology is thought to involve choroidal vascular compromise, leading to secondary ischemia and inflammation of the RPE. Although the precise etiology remains unclear, approximately one-third of patients report a preceding viral-like illness, supporting the possibility of an immune-mediated or post-infectious mechanism.
Patients typically present with sudden, painless visual loss, which may affect one or both eyes. Visual symptoms can include blurred vision or scotomas. On funduscopic examination, characteristic findings include multiple, flat, yellowish-white lesions at the level of the RPE and choroid, often located in the macular region. These lesions may appear in various stages, with some resolving while others are newly forming. As lesions heal, they leave behind areas of pigmentary change due to RPE alteration.
Fluorescein angiography is helpful in confirming the diagnosis, demonstrating early hypofluorescence of the lesions due to blockage or nonperfusion, followed by late hyperfluorescence as dye leaks into the affected areas. The differential diagnosis includes other inflammatory and infectious chorioretinal diseases such as serpiginous choroiditis, ampiginous chorioretinitis, ocular toxoplasmosis, sarcoidosis, ocular lymphoma, and Vogt-Koyanagi-Harada disease.
Management is typically conservative, as most cases resolve spontaneously without treatment within several weeks. Visual recovery usually occurs over 3 to 4 weeks. In cases where the fovea is involved and vision is significantly affected, a short course of systemic corticosteroids may be considered, although evidence supporting this approach is limited. Patients should be referred to a retinal specialist for confirmation of diagnosis and monitoring.
Close follow-up is important to ensure resolution and to monitor for rare complications. Recurrence is uncommon, and repeated episodes should prompt reconsideration of the diagnosis. A critical but rare complication is cerebral vasculitis, which can be life-threatening; therefore, any associated neurological symptoms such as altered mental status require urgent neurological evaluation. The prognosis is generally favorable, with most patients regaining good visual acuity unless significant RPE damage occurs in the foveal region.
- Published on
Ophthalmology – Dry Age-Related Macular Degeneration (AMD)
Dry age-related macular degeneration is a chronic degenerative condition affecting the macula and is a major cause of vision loss in elderly populations, particularly among individuals of European descent. It primarily involves the outer retina, retinal pigment epithelium (RPE), Bruch’s membrane, and the choriocapillaris. Although it is less likely to cause rapid or severe vision loss compared to the wet (exudative) form, it still accounts for a significant proportion of legal blindness in patients over 65 years of age. The disease is characterized by the presence of drusen, pigmentary changes, and in advanced stages, geographic atrophy.
The incidence and prevalence of dry AMD increase with age, with early disease affecting millions of individuals. The development of large drusen or pigmentary changes occurs more frequently in older age groups, and progression to advanced AMD, including geographic atrophy or neovascular AMD, becomes more likely with advancing age. Risk factors include increasing age, family history, Caucasian ethnicity, smoking, and possibly cardiovascular risk factors. Genetic predisposition plays a significant role, with variants in genes such as complement factor H (CFH), complement factor B, and HTRA1 contributing to disease susceptibility.
The pathophysiology involves degenerative changes in the RPE and Bruch’s membrane, with accumulation of metabolic waste products and formation of drusen. These deposits may be classified as hard or soft drusen, with soft drusen being more strongly associated with disease progression. Over time, dysfunction and loss of the RPE can lead to photoreceptor degeneration and geographic atrophy. Oxidative stress and accumulation of lipofuscin components, such as A2E, are thought to contribute to RPE cell death and disease progression.
Patients with early dry AMD are often asymptomatic and may be diagnosed during routine examination. As the disease progresses, symptoms may include gradual central vision loss, distortion (metamorphopsia), or the appearance of central scotomas. The condition is typically bilateral but often asymmetric. Sudden worsening of vision or distortion may indicate progression to the exudative form and requires urgent evaluation.
On examination, characteristic findings include drusen of varying size and appearance, pigmentary changes in the RPE, and areas of retinal thinning or atrophy. Geographic atrophy appears as well-defined areas of RPE loss, while earlier changes may include mottled pigmentation. The classification of AMD into early, intermediate, and advanced stages is based on the size and extent of drusen and the presence of atrophy or neovascular changes.
Diagnosis and monitoring rely on imaging techniques such as optical coherence tomography, which can identify drusen, RPE abnormalities, and areas of atrophy, as well as detect early signs of progression to wet AMD. Fluorescein angiography may be used in cases of suspected neovascularization, and fundus autofluorescence can help assess RPE health and areas of damage. Risk of progression can be estimated using the AREDS simplified severity score, which incorporates features such as large drusen, pigmentary abnormalities, and involvement of both eyes.
Management focuses on slowing disease progression and monitoring for complications. The Age-Related Eye Disease Study demonstrated that antioxidant vitamin supplementation, including vitamins C and E, zinc, beta-carotene, and copper, can reduce the risk of progression in patients with intermediate or advanced AMD. However, beta-carotene should be avoided in smokers due to increased risk of lung cancer. Lifestyle modifications, particularly smoking cessation and a diet rich in leafy green vegetables and omega-3 fatty acids, are strongly recommended. Patients should also be advised to regularly monitor their vision using an Amsler grid to detect early changes suggestive of progression.
There is no role for laser photocoagulation in dry AMD, and current management is largely supportive. Regular ophthalmologic follow-up is essential to monitor disease progression and detect conversion to the wet form, which requires different treatment. The prognosis varies, with many patients maintaining functional vision for years, although some will progress to advanced stages with significant central vision loss.
Dry age-related macular degeneration is a chronic degenerative condition affecting the macula and is a major cause of vision loss in elderly populations, particularly among individuals of European descent. It primarily involves the outer retina, retinal pigment epithelium (RPE), Bruch’s membrane, and the choriocapillaris. Although it is less likely to cause rapid or severe vision loss compared to the wet (exudative) form, it still accounts for a significant proportion of legal blindness in patients over 65 years of age. The disease is characterized by the presence of drusen, pigmentary changes, and in advanced stages, geographic atrophy.
The incidence and prevalence of dry AMD increase with age, with early disease affecting millions of individuals. The development of large drusen or pigmentary changes occurs more frequently in older age groups, and progression to advanced AMD, including geographic atrophy or neovascular AMD, becomes more likely with advancing age. Risk factors include increasing age, family history, Caucasian ethnicity, smoking, and possibly cardiovascular risk factors. Genetic predisposition plays a significant role, with variants in genes such as complement factor H (CFH), complement factor B, and HTRA1 contributing to disease susceptibility.
The pathophysiology involves degenerative changes in the RPE and Bruch’s membrane, with accumulation of metabolic waste products and formation of drusen. These deposits may be classified as hard or soft drusen, with soft drusen being more strongly associated with disease progression. Over time, dysfunction and loss of the RPE can lead to photoreceptor degeneration and geographic atrophy. Oxidative stress and accumulation of lipofuscin components, such as A2E, are thought to contribute to RPE cell death and disease progression.
Patients with early dry AMD are often asymptomatic and may be diagnosed during routine examination. As the disease progresses, symptoms may include gradual central vision loss, distortion (metamorphopsia), or the appearance of central scotomas. The condition is typically bilateral but often asymmetric. Sudden worsening of vision or distortion may indicate progression to the exudative form and requires urgent evaluation.
On examination, characteristic findings include drusen of varying size and appearance, pigmentary changes in the RPE, and areas of retinal thinning or atrophy. Geographic atrophy appears as well-defined areas of RPE loss, while earlier changes may include mottled pigmentation. The classification of AMD into early, intermediate, and advanced stages is based on the size and extent of drusen and the presence of atrophy or neovascular changes.
Diagnosis and monitoring rely on imaging techniques such as optical coherence tomography, which can identify drusen, RPE abnormalities, and areas of atrophy, as well as detect early signs of progression to wet AMD. Fluorescein angiography may be used in cases of suspected neovascularization, and fundus autofluorescence can help assess RPE health and areas of damage. Risk of progression can be estimated using the AREDS simplified severity score, which incorporates features such as large drusen, pigmentary abnormalities, and involvement of both eyes.
Management focuses on slowing disease progression and monitoring for complications. The Age-Related Eye Disease Study demonstrated that antioxidant vitamin supplementation, including vitamins C and E, zinc, beta-carotene, and copper, can reduce the risk of progression in patients with intermediate or advanced AMD. However, beta-carotene should be avoided in smokers due to increased risk of lung cancer. Lifestyle modifications, particularly smoking cessation and a diet rich in leafy green vegetables and omega-3 fatty acids, are strongly recommended. Patients should also be advised to regularly monitor their vision using an Amsler grid to detect early changes suggestive of progression.
There is no role for laser photocoagulation in dry AMD, and current management is largely supportive. Regular ophthalmologic follow-up is essential to monitor disease progression and detect conversion to the wet form, which requires different treatment. The prognosis varies, with many patients maintaining functional vision for years, although some will progress to advanced stages with significant central vision loss.
- Published on
Ophthalmology – Allergic Conjunctivitis
Allergic conjunctivitis is an inflammatory condition of the ocular surface caused by hypersensitivity reactions to environmental allergens and is one of the most common eye disorders, affecting up to 40% of the population. It encompasses several subtypes, including seasonal allergic conjunctivitis (SAC), perennial allergic conjunctivitis (PAC), vernal keratoconjunctivitis (VKC), atopic keratoconjunctivitis (AKC), and giant papillary conjunctivitis (GPC). SAC occurs during specific times of the year, typically related to pollen exposure, while PAC persists year-round due to indoor allergens such as dust mites or animal dander. VKC and AKC are more severe, chronic forms often involving the cornea, and GPC is typically associated with mechanical irritation, such as contact lens wear or ocular prostheses.
The condition is strongly associated with atopic disease, including asthma, eczema, allergic rhinitis, and hay fever, and often occurs in individuals with a personal or family history of these conditions. VKC tends to affect young males in warm climates and often improves after puberty, whereas AKC occurs in older individuals and is associated with atopic dermatitis. GPC is linked to chronic mechanical irritation rather than classic allergy alone. The underlying pathophysiology involves activation of mast cells in response to allergens, leading to release of histamine and other inflammatory mediators. SAC and PAC are primarily type I hypersensitivity reactions, while VKC and AKC involve both type I and type IV hypersensitivity mechanisms.
Patients commonly present with itching, which is the hallmark symptom, along with redness, tearing, burning, photophobia, and watery discharge. SAC symptoms typically correlate with seasonal allergen exposure, while PAC symptoms are more persistent. VKC presents with intense itching and is often bilateral, while AKC may have chronic symptoms with associated eyelid dermatitis. GPC is often associated with contact lens intolerance and mucous discharge. On examination, SAC and PAC show mild conjunctival injection and papillary reactions without large papillae. VKC is characterized by giant papillae on the upper tarsal conjunctiva, limbal thickening, and Trantas’ dots, with possible corneal involvement such as punctate keratopathy or shield ulcers. AKC may show eyelid eczema, papillary hypertrophy, and corneal scarring or pannus. GPC presents with large papillae on the superior tarsal conjunctiva.
Diagnosis is primarily clinical and does not usually require laboratory testing, although conjunctival scrapings may reveal eosinophils. Differential diagnoses include viral conjunctivitis, dry eye disease, blepharitis, contact dermatitis, toxic or chemical conjunctivitis, and floppy eyelid syndrome. Management focuses on allergen avoidance and symptom control. First-line treatment for mild cases includes topical antihistamines, mast cell stabilizers, or combination agents such as olopatadine or ketotifen. Artificial tears can help dilute allergens and soothe the ocular surface. In more severe cases, especially VKC and AKC, topical corticosteroids may be required but should be used cautiously due to potential side effects such as glaucoma, cataract formation, and increased risk of infection. Topical cyclosporine may be used in chronic or steroid-dependent cases.
For GPC, management includes improving contact lens hygiene, reducing lens wear, or temporarily discontinuing lens use. Additional supportive measures include avoiding known triggers, staying in cool environments, and using preservative-free artificial tears frequently. Patients with significant corneal involvement or vision-threatening complications should be referred to an ophthalmologist for specialized care. Surgical interventions, such as superficial keratectomy or tarsorrhaphy, may be required in severe refractory cases.
The prognosis is generally good for SAC, PAC, and GPC, with symptoms being manageable and often intermittent. However, VKC and AKC can have a more guarded prognosis due to potential corneal complications, including scarring and vision loss. Regular follow-up is important in these cases, particularly when using topical steroids, to monitor intraocular pressure and lens clarity.
Allergic conjunctivitis is an inflammatory condition of the ocular surface caused by hypersensitivity reactions to environmental allergens and is one of the most common eye disorders, affecting up to 40% of the population. It encompasses several subtypes, including seasonal allergic conjunctivitis (SAC), perennial allergic conjunctivitis (PAC), vernal keratoconjunctivitis (VKC), atopic keratoconjunctivitis (AKC), and giant papillary conjunctivitis (GPC). SAC occurs during specific times of the year, typically related to pollen exposure, while PAC persists year-round due to indoor allergens such as dust mites or animal dander. VKC and AKC are more severe, chronic forms often involving the cornea, and GPC is typically associated with mechanical irritation, such as contact lens wear or ocular prostheses.
The condition is strongly associated with atopic disease, including asthma, eczema, allergic rhinitis, and hay fever, and often occurs in individuals with a personal or family history of these conditions. VKC tends to affect young males in warm climates and often improves after puberty, whereas AKC occurs in older individuals and is associated with atopic dermatitis. GPC is linked to chronic mechanical irritation rather than classic allergy alone. The underlying pathophysiology involves activation of mast cells in response to allergens, leading to release of histamine and other inflammatory mediators. SAC and PAC are primarily type I hypersensitivity reactions, while VKC and AKC involve both type I and type IV hypersensitivity mechanisms.
Patients commonly present with itching, which is the hallmark symptom, along with redness, tearing, burning, photophobia, and watery discharge. SAC symptoms typically correlate with seasonal allergen exposure, while PAC symptoms are more persistent. VKC presents with intense itching and is often bilateral, while AKC may have chronic symptoms with associated eyelid dermatitis. GPC is often associated with contact lens intolerance and mucous discharge. On examination, SAC and PAC show mild conjunctival injection and papillary reactions without large papillae. VKC is characterized by giant papillae on the upper tarsal conjunctiva, limbal thickening, and Trantas’ dots, with possible corneal involvement such as punctate keratopathy or shield ulcers. AKC may show eyelid eczema, papillary hypertrophy, and corneal scarring or pannus. GPC presents with large papillae on the superior tarsal conjunctiva.
Diagnosis is primarily clinical and does not usually require laboratory testing, although conjunctival scrapings may reveal eosinophils. Differential diagnoses include viral conjunctivitis, dry eye disease, blepharitis, contact dermatitis, toxic or chemical conjunctivitis, and floppy eyelid syndrome. Management focuses on allergen avoidance and symptom control. First-line treatment for mild cases includes topical antihistamines, mast cell stabilizers, or combination agents such as olopatadine or ketotifen. Artificial tears can help dilute allergens and soothe the ocular surface. In more severe cases, especially VKC and AKC, topical corticosteroids may be required but should be used cautiously due to potential side effects such as glaucoma, cataract formation, and increased risk of infection. Topical cyclosporine may be used in chronic or steroid-dependent cases.
For GPC, management includes improving contact lens hygiene, reducing lens wear, or temporarily discontinuing lens use. Additional supportive measures include avoiding known triggers, staying in cool environments, and using preservative-free artificial tears frequently. Patients with significant corneal involvement or vision-threatening complications should be referred to an ophthalmologist for specialized care. Surgical interventions, such as superficial keratectomy or tarsorrhaphy, may be required in severe refractory cases.
The prognosis is generally good for SAC, PAC, and GPC, with symptoms being manageable and often intermittent. However, VKC and AKC can have a more guarded prognosis due to potential corneal complications, including scarring and vision loss. Regular follow-up is important in these cases, particularly when using topical steroids, to monitor intraocular pressure and lens clarity.
- Published on
Ophthalmology – Albinism
Albinism refers to a group of inherited disorders characterized by reduced or absent melanin production due to defects in melanin synthesis or melanosome formation. It is broadly classified into oculocutaneous albinism (OCA), which affects the skin, hair, and eyes, and ocular albinism (OA), which primarily involves the eyes. OCA includes several subtypes (OCA1–OCA4), each caused by different genetic mutations but often showing overlapping clinical features. OCA1 typically presents with white hair, pale skin, and light irides, while OCA2 tends to be milder and is more common in African and certain Native American populations. OCA3 presents with brown or reddish pigmentation and is more frequent in African populations, whereas OCA4 resembles OCA2 and is more common in parts of Asia. Ocular albinism, most commonly the Nettleship-Falls type, is usually X-linked and primarily affects males, with females often being carriers.
The condition occurs worldwide with an incidence of approximately 1 in 20,000 births, and about 1 in 17,000 individuals are affected by some form of albinism. Genetic inheritance for OCA is usually autosomal recessive, involving mutations in genes such as TYR, OCA2, TYRP1, and SLC45A2, while OA is typically X-linked recessive involving the GPR143 gene. The pathophysiology involves hypopigmentation of the retinal pigment epithelium during development, leading to abnormal foveal formation (macular hypoplasia), delayed retinal ganglion cell development, and misrouting of optic nerve fibers at the optic chiasm.
Clinically, patients present with a range of ocular findings including congenital nystagmus, strabismus, reduced visual acuity (typically between 20/40 and 20/400), refractive errors, amblyopia, iris transillumination, photophobia, and hypopigmented fundus with visible choroidal vasculature. Macular hypoplasia is a key feature contributing to reduced vision. Optic nerves may appear gray and may show hypoplasia. Cutaneous features in OCA include hypopigmented skin and hair, with some individuals developing freckles or nevi. A detailed history should include family history, visual symptoms, photosensitivity, and systemic features such as easy bruising or recurrent infections, which may suggest associated syndromes.
Albinism can be associated with systemic conditions such as Hermansky–Pudlak syndrome, which includes platelet dysfunction and risk of bleeding as well as pulmonary and gastrointestinal complications; Chediak–Higashi syndrome, which involves immune deficiency and recurrent infections; and Griscelli syndrome, which may include neurological or immunological abnormalities. It may also be seen in syndromes such as Prader-Willi and Angelman syndromes.
Diagnosis is primarily clinical but may be supported by genetic testing to identify specific mutations. Optical coherence tomography demonstrates macular hypoplasia, and visual evoked potential testing reveals abnormal decussation of optic nerve fibers. Skin biopsy in certain forms may show characteristic macromelanosomes. Prenatal diagnosis is possible if the genetic mutation is known.
Management is supportive and aimed at optimizing vision and protecting the skin. Refractive errors should be corrected with glasses or contact lenses, and amblyopia should be treated when present. Tinted lenses can help reduce photophobia, and low vision aids such as magnifiers and high-contrast reading materials can improve functional vision. Sun protection is essential, including the use of sunscreen and protective clothing, due to the increased risk of skin damage and malignancy.
Patients require regular follow-up with ophthalmology, low vision services, and dermatology for skin monitoring. Hematology evaluation may be necessary if syndromic associations are suspected. The overall prognosis is generally good in terms of lifespan, development, and fertility, although visual acuity remains reduced and patients are at increased risk for skin cancers such as basal cell carcinoma, squamous cell carcinoma, and actinic keratosis.
Albinism refers to a group of inherited disorders characterized by reduced or absent melanin production due to defects in melanin synthesis or melanosome formation. It is broadly classified into oculocutaneous albinism (OCA), which affects the skin, hair, and eyes, and ocular albinism (OA), which primarily involves the eyes. OCA includes several subtypes (OCA1–OCA4), each caused by different genetic mutations but often showing overlapping clinical features. OCA1 typically presents with white hair, pale skin, and light irides, while OCA2 tends to be milder and is more common in African and certain Native American populations. OCA3 presents with brown or reddish pigmentation and is more frequent in African populations, whereas OCA4 resembles OCA2 and is more common in parts of Asia. Ocular albinism, most commonly the Nettleship-Falls type, is usually X-linked and primarily affects males, with females often being carriers.
The condition occurs worldwide with an incidence of approximately 1 in 20,000 births, and about 1 in 17,000 individuals are affected by some form of albinism. Genetic inheritance for OCA is usually autosomal recessive, involving mutations in genes such as TYR, OCA2, TYRP1, and SLC45A2, while OA is typically X-linked recessive involving the GPR143 gene. The pathophysiology involves hypopigmentation of the retinal pigment epithelium during development, leading to abnormal foveal formation (macular hypoplasia), delayed retinal ganglion cell development, and misrouting of optic nerve fibers at the optic chiasm.
Clinically, patients present with a range of ocular findings including congenital nystagmus, strabismus, reduced visual acuity (typically between 20/40 and 20/400), refractive errors, amblyopia, iris transillumination, photophobia, and hypopigmented fundus with visible choroidal vasculature. Macular hypoplasia is a key feature contributing to reduced vision. Optic nerves may appear gray and may show hypoplasia. Cutaneous features in OCA include hypopigmented skin and hair, with some individuals developing freckles or nevi. A detailed history should include family history, visual symptoms, photosensitivity, and systemic features such as easy bruising or recurrent infections, which may suggest associated syndromes.
Albinism can be associated with systemic conditions such as Hermansky–Pudlak syndrome, which includes platelet dysfunction and risk of bleeding as well as pulmonary and gastrointestinal complications; Chediak–Higashi syndrome, which involves immune deficiency and recurrent infections; and Griscelli syndrome, which may include neurological or immunological abnormalities. It may also be seen in syndromes such as Prader-Willi and Angelman syndromes.
Diagnosis is primarily clinical but may be supported by genetic testing to identify specific mutations. Optical coherence tomography demonstrates macular hypoplasia, and visual evoked potential testing reveals abnormal decussation of optic nerve fibers. Skin biopsy in certain forms may show characteristic macromelanosomes. Prenatal diagnosis is possible if the genetic mutation is known.
Management is supportive and aimed at optimizing vision and protecting the skin. Refractive errors should be corrected with glasses or contact lenses, and amblyopia should be treated when present. Tinted lenses can help reduce photophobia, and low vision aids such as magnifiers and high-contrast reading materials can improve functional vision. Sun protection is essential, including the use of sunscreen and protective clothing, due to the increased risk of skin damage and malignancy.
Patients require regular follow-up with ophthalmology, low vision services, and dermatology for skin monitoring. Hematology evaluation may be necessary if syndromic associations are suspected. The overall prognosis is generally good in terms of lifespan, development, and fertility, although visual acuity remains reduced and patients are at increased risk for skin cancers such as basal cell carcinoma, squamous cell carcinoma, and actinic keratosis.
- Published on
Ophthalmology – Aicardi Syndrome
Aicardi syndrome is a rare genetic neurodevelopmental disorder classically defined by a triad of infantile spasms, agenesis of the corpus callosum, and distinctive chorioretinal lacunae. It primarily affects females and is presumed to follow an X-linked dominant inheritance pattern that is typically lethal in males, with rare surviving males often having chromosomal abnormalities such as XXY. The condition is extremely rare, with only several thousand cases reported worldwide. The exact gene responsible has not been definitively identified, and the disorder is thought to arise from a developmental defect of neuroectodermal origin.
The syndrome is associated with a wide range of ocular and systemic abnormalities. The hallmark ocular finding is chorioretinal lacunae, which are areas of retinal pigment epithelium and choroidal atrophy with disrupted overlying retinal architecture. Additional ocular features may include optic disc anomalies such as coloboma or hypoplasia, microphthalmia, retinal detachment, and nystagmus. Systemically, patients often have significant central nervous system malformations, including partial or complete agenesis of the corpus callosum, cortical malformations such as polymicrogyria or pachygyria, heterotopias, intracranial cysts, ventriculomegaly, and cerebral asymmetry. Other associated abnormalities include vertebral and rib malformations, hypotonia, microcephaly, dysmorphic facial features, gastrointestinal disturbances, and skin lesions. Severe developmental delay and intellectual disability are common.
Affected infants typically present between 3 and 5 months of age with neurological symptoms such as developmental delay, hypotonia, and intractable infantile spasms. Ocular findings such as decreased visual acuity, amblyopia, or strabismus may also be noted. Diagnosis is based on clinical features, with the presence of the classic triad being diagnostic. Cases with two components of the triad plus additional major or supporting features are strongly suggestive. Neuroimaging, particularly MRI, is essential to identify structural brain abnormalities, and EEG often demonstrates characteristic patterns such as hypsarrhythmia associated with infantile spasms. Routine laboratory tests are typically normal, although genetic testing such as karyotyping and microarray analysis may be performed to evaluate chromosomal abnormalities.
The differential diagnosis includes other conditions with corpus callosum agenesis, neuronal migration disorders, infantile spasms of other etiologies, and syndromes with overlapping ocular or neurological findings such as oculocerebrocutaneous syndrome. Chorioretinal lacunae are considered highly characteristic of Aicardi syndrome but may rarely be seen in other conditions.
Management is supportive and multidisciplinary, focusing on seizure control and addressing developmental and systemic complications. Antiepileptic medications, particularly vigabatrin, are commonly used, and some patients may benefit from vagus nerve stimulation. Physical, occupational, and speech therapies are important for supportive care. Regular ophthalmologic follow-up is recommended, particularly if medications such as vigabatrin are used due to potential retinal toxicity. Referral to neurology and other specialties is often necessary to manage the complex needs of these patients.
Prognosis is variable but generally poor due to severe neurological impairment. Many patients have significant developmental delay and require lifelong care. Vision is often limited more by cortical visual impairment than by ocular abnormalities unless the macula is involved. Life expectancy is reduced, with many patients succumbing to complications such as intractable seizures, aspiration, or complications related to severe neurological disability, although some individuals may survive into adolescence or adulthood.
Aicardi syndrome is a rare genetic neurodevelopmental disorder classically defined by a triad of infantile spasms, agenesis of the corpus callosum, and distinctive chorioretinal lacunae. It primarily affects females and is presumed to follow an X-linked dominant inheritance pattern that is typically lethal in males, with rare surviving males often having chromosomal abnormalities such as XXY. The condition is extremely rare, with only several thousand cases reported worldwide. The exact gene responsible has not been definitively identified, and the disorder is thought to arise from a developmental defect of neuroectodermal origin.
The syndrome is associated with a wide range of ocular and systemic abnormalities. The hallmark ocular finding is chorioretinal lacunae, which are areas of retinal pigment epithelium and choroidal atrophy with disrupted overlying retinal architecture. Additional ocular features may include optic disc anomalies such as coloboma or hypoplasia, microphthalmia, retinal detachment, and nystagmus. Systemically, patients often have significant central nervous system malformations, including partial or complete agenesis of the corpus callosum, cortical malformations such as polymicrogyria or pachygyria, heterotopias, intracranial cysts, ventriculomegaly, and cerebral asymmetry. Other associated abnormalities include vertebral and rib malformations, hypotonia, microcephaly, dysmorphic facial features, gastrointestinal disturbances, and skin lesions. Severe developmental delay and intellectual disability are common.
Affected infants typically present between 3 and 5 months of age with neurological symptoms such as developmental delay, hypotonia, and intractable infantile spasms. Ocular findings such as decreased visual acuity, amblyopia, or strabismus may also be noted. Diagnosis is based on clinical features, with the presence of the classic triad being diagnostic. Cases with two components of the triad plus additional major or supporting features are strongly suggestive. Neuroimaging, particularly MRI, is essential to identify structural brain abnormalities, and EEG often demonstrates characteristic patterns such as hypsarrhythmia associated with infantile spasms. Routine laboratory tests are typically normal, although genetic testing such as karyotyping and microarray analysis may be performed to evaluate chromosomal abnormalities.
The differential diagnosis includes other conditions with corpus callosum agenesis, neuronal migration disorders, infantile spasms of other etiologies, and syndromes with overlapping ocular or neurological findings such as oculocerebrocutaneous syndrome. Chorioretinal lacunae are considered highly characteristic of Aicardi syndrome but may rarely be seen in other conditions.
Management is supportive and multidisciplinary, focusing on seizure control and addressing developmental and systemic complications. Antiepileptic medications, particularly vigabatrin, are commonly used, and some patients may benefit from vagus nerve stimulation. Physical, occupational, and speech therapies are important for supportive care. Regular ophthalmologic follow-up is recommended, particularly if medications such as vigabatrin are used due to potential retinal toxicity. Referral to neurology and other specialties is often necessary to manage the complex needs of these patients.
Prognosis is variable but generally poor due to severe neurological impairment. Many patients have significant developmental delay and require lifelong care. Vision is often limited more by cortical visual impairment than by ocular abnormalities unless the macula is involved. Life expectancy is reduced, with many patients succumbing to complications such as intractable seizures, aspiration, or complications related to severe neurological disability, although some individuals may survive into adolescence or adulthood.
- Published on
Ophthalmology – Age-Related (Senile) Retinoschisis
Age-related (senile) retinoschisis is an acquired retinal condition characterized by splitting of the neurosensory retina into two distinct layers, most commonly occurring in the peripheral retina. It is generally a benign and slowly progressive condition, often discovered incidentally during routine eye examination. The prevalence ranges from approximately 1.65% to 7% in individuals over 40 years of age, with equal distribution between males and females. It is frequently associated with hyperopia and preexisting peripheral cystoid degeneration, although the exact genetic basis remains unknown.
The condition develops as intraretinal cysts coalesce within areas of peripheral cystoid degeneration, typically beginning near the ora serrata and extending posteriorly. The splitting most often occurs in the outer plexiform layer in the typical form, while a less common reticular form involves splitting in the nerve fiber layer. Vision is usually unaffected as long as the schisis cavity remains confined to the peripheral retina. However, visual impairment can occur if the schisis extends toward the macula, which is uncommon, or if a rhegmatogenous retinal detachment develops as a complication.
Patients are usually asymptomatic, though some may report peripheral visual field defects, flashes, floaters, or rarely central vision loss if complications arise. On dilated fundus examination, the lesion appears as a smooth, dome-shaped elevation of the retina that is immobile and does not undulate with eye movement. It is often located inferotemporally and may be bilateral, though frequently asymmetric. Additional findings include peripheral cystoid degeneration anterior to the schisis, presence of inner or outer retinal holes, fine white surface dots, and sclerosed retinal vessels within the affected area. A distinguishing feature is that the inner retinal layer does not collapse with scleral depression.
Diagnosis is primarily clinical, supported by fundus examination and sometimes imaging. Fundus photography may be used to document the extent of the lesion for follow-up. Visual field testing typically reveals an absolute scotoma corresponding to the area of schisis. Optical coherence tomography can help differentiate retinoschisis from retinal detachment by demonstrating splitting of the retinal layers rather than complete separation from the retinal pigment epithelium.
The most important differential diagnosis is rhegmatogenous retinal detachment, which may appear similar but often shows additional features such as vitreous pigment or a demarcation line. Differentiation can sometimes be challenging; however, laser retinopexy produces a visible burn in retinoschisis but not in retinal detachment, and OCT provides definitive structural distinction. Other features such as mobility of the retina and collapse with scleral depression can also aid in differentiation.
Management is usually conservative, as most cases remain stable and do not significantly affect vision. Observation with periodic follow-up is the standard approach, typically every 1 to 3 years for uncomplicated cases. In cases where the schisis extends posteriorly or is associated with retinal breaks, closer monitoring is required. Intervention such as laser retinopexy or cryotherapy may be considered in select cases, although treatment is often avoided due to the low risk of progression and the potential to induce complications. If a rhegmatogenous retinal detachment develops, surgical repair with scleral buckle or pars plana vitrectomy is indicated.
The prognosis is generally excellent, with most patients maintaining stable vision over time. However, outcomes may worsen if complications such as retinal detachment occur. Patients should be educated to seek prompt evaluation if they experience new visual symptoms such as flashes, floaters, or changes in vision. The key clinical consideration is distinguishing this condition from retinal detachment and ensuring appropriate monitoring for potential progression or complications.
Age-related (senile) retinoschisis is an acquired retinal condition characterized by splitting of the neurosensory retina into two distinct layers, most commonly occurring in the peripheral retina. It is generally a benign and slowly progressive condition, often discovered incidentally during routine eye examination. The prevalence ranges from approximately 1.65% to 7% in individuals over 40 years of age, with equal distribution between males and females. It is frequently associated with hyperopia and preexisting peripheral cystoid degeneration, although the exact genetic basis remains unknown.
The condition develops as intraretinal cysts coalesce within areas of peripheral cystoid degeneration, typically beginning near the ora serrata and extending posteriorly. The splitting most often occurs in the outer plexiform layer in the typical form, while a less common reticular form involves splitting in the nerve fiber layer. Vision is usually unaffected as long as the schisis cavity remains confined to the peripheral retina. However, visual impairment can occur if the schisis extends toward the macula, which is uncommon, or if a rhegmatogenous retinal detachment develops as a complication.
Patients are usually asymptomatic, though some may report peripheral visual field defects, flashes, floaters, or rarely central vision loss if complications arise. On dilated fundus examination, the lesion appears as a smooth, dome-shaped elevation of the retina that is immobile and does not undulate with eye movement. It is often located inferotemporally and may be bilateral, though frequently asymmetric. Additional findings include peripheral cystoid degeneration anterior to the schisis, presence of inner or outer retinal holes, fine white surface dots, and sclerosed retinal vessels within the affected area. A distinguishing feature is that the inner retinal layer does not collapse with scleral depression.
Diagnosis is primarily clinical, supported by fundus examination and sometimes imaging. Fundus photography may be used to document the extent of the lesion for follow-up. Visual field testing typically reveals an absolute scotoma corresponding to the area of schisis. Optical coherence tomography can help differentiate retinoschisis from retinal detachment by demonstrating splitting of the retinal layers rather than complete separation from the retinal pigment epithelium.
The most important differential diagnosis is rhegmatogenous retinal detachment, which may appear similar but often shows additional features such as vitreous pigment or a demarcation line. Differentiation can sometimes be challenging; however, laser retinopexy produces a visible burn in retinoschisis but not in retinal detachment, and OCT provides definitive structural distinction. Other features such as mobility of the retina and collapse with scleral depression can also aid in differentiation.
Management is usually conservative, as most cases remain stable and do not significantly affect vision. Observation with periodic follow-up is the standard approach, typically every 1 to 3 years for uncomplicated cases. In cases where the schisis extends posteriorly or is associated with retinal breaks, closer monitoring is required. Intervention such as laser retinopexy or cryotherapy may be considered in select cases, although treatment is often avoided due to the low risk of progression and the potential to induce complications. If a rhegmatogenous retinal detachment develops, surgical repair with scleral buckle or pars plana vitrectomy is indicated.
The prognosis is generally excellent, with most patients maintaining stable vision over time. However, outcomes may worsen if complications such as retinal detachment occur. Patients should be educated to seek prompt evaluation if they experience new visual symptoms such as flashes, floaters, or changes in vision. The key clinical consideration is distinguishing this condition from retinal detachment and ensuring appropriate monitoring for potential progression or complications.
- Published on
Ophthalmology – Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy
Age-related macular degeneration (AMD) is a leading cause of irreversible vision loss among older adults, particularly in developed countries, and is the most common cause of legal blindness in individuals aged 65 years and older in the United States. It is broadly classified into two forms: non-exudative (“dry”) AMD, which accounts for approximately 90% of cases, and exudative (“wet”) AMD, which represents about 10% but is responsible for the majority of severe vision loss. Polypoidal choroidal vasculopathy (PCV) is a distinct clinical entity from AMD, characterized by abnormalities in the inner choroidal vasculature, including a branching network of dilated vessels that lead to serous leakage and hemorrhage. PCV is more commonly seen in Asian and African or African American populations, while it is less frequent in Caucasians.
The incidence and prevalence of AMD increase significantly with age. Early AMD rises from about 3.9% in individuals aged 43–54 years to over 20% in those older than 75 years, while late AMD has a 5-year incidence of approximately 0.9%. Overall prevalence of AMD in adults over 40 years is around 9.2%. PCV prevalence varies widely, ranging from 4% to 14%, and may be significantly higher in certain populations, such as Japanese patients diagnosed with AMD. Risk factors for AMD include advancing age, family history, Caucasian race, smoking, hypertension, hyperlipidemia, obesity, and female gender. In contrast, PCV is more strongly associated with ethnicity and age.
Genetic factors play an important role in AMD, with associations identified in genes such as complement factor H (CFH), LOC387715, and HTRA1, with certain variants significantly increasing disease risk. PCV shares some genetic associations, particularly involving LOC387715 and HTRA1. The pathophysiology of AMD is multifactorial and includes degeneration of the retinal pigment epithelium (RPE), accumulation of photoreceptor debris forming drusen, reduced choroidal circulation leading to ischemia, and genetic susceptibility. In the exudative form, abnormal choroidal neovascular membranes develop beneath the retina or RPE, causing leakage and hemorrhage. In PCV, abnormalities in the inner choroidal vasculature result in polyp-like dilations and vascular networks that leak or bleed beneath the RPE.
Patients with AMD or PCV may present with central visual disturbances such as blurring, distortion (metamorphopsia), central scotomas, or may be asymptomatic in early stages. On examination, non-exudative AMD is characterized by drusen, pigmentary changes in the RPE, and eventual retinal thinning or geographic atrophy. Exudative AMD may show subretinal or intraretinal fluid, hemorrhage, lipid exudates, pigment epithelial detachment, or retinal pigment epithelial tears. PCV should be suspected in patients with exudative maculopathy, particularly in non-Caucasian individuals, those with peripapillary lesions, or cases with minimal drusen in the fellow eye.
Diagnosis relies heavily on imaging. Optical coherence tomography (OCT) is essential for identifying fluid, retinal thickening, and monitoring disease progression. Fluorescein angiography is used to identify and characterize choroidal neovascularization in AMD. Indocyanine green angiography is particularly useful in PCV for visualizing the characteristic polypoidal vascular lesions and branching networks. These imaging modalities are also critical in guiding treatment decisions and monitoring response to therapy.
Management of AMD depends on the stage and type of disease. For exudative AMD, intravitreal anti-vascular endothelial growth factor (anti-VEGF) agents such as bevacizumab and ranibizumab are the mainstay of treatment and have significantly improved visual outcomes. Additional therapies may include photodynamic therapy, thermal laser for selected cases, intravitreal steroids, or combination regimens in refractory cases. For non-exudative AMD, there is no curative treatment, but progression may be slowed with lifestyle modification and nutritional supplementation using AREDS formulations, which include vitamins C and E, zinc, beta-carotene, and copper. Risk factor modification, including smoking cessation and control of cardiovascular risk factors, is essential.
Management of PCV differs somewhat, with photodynamic therapy often playing a central role, particularly for subfoveal lesions. Anti-VEGF therapy is also used but may be less effective compared to its role in AMD, and combination therapy with anti-VEGF agents and photodynamic therapy has shown promising results. Referral to a retinal specialist is essential for both AMD and PCV to ensure appropriate diagnosis and management.
Patients require ongoing monitoring, including regular ophthalmologic evaluations and use of home Amsler grid testing to detect changes in vision. Low vision support may be necessary for those with significant visual impairment. Prognosis varies, with many patients maintaining functional vision with treatment, although both AMD and PCV can lead to progressive central vision loss. Despite this, these conditions do not affect overall lifespan or systemic health.
Age-related macular degeneration (AMD) is a leading cause of irreversible vision loss among older adults, particularly in developed countries, and is the most common cause of legal blindness in individuals aged 65 years and older in the United States. It is broadly classified into two forms: non-exudative (“dry”) AMD, which accounts for approximately 90% of cases, and exudative (“wet”) AMD, which represents about 10% but is responsible for the majority of severe vision loss. Polypoidal choroidal vasculopathy (PCV) is a distinct clinical entity from AMD, characterized by abnormalities in the inner choroidal vasculature, including a branching network of dilated vessels that lead to serous leakage and hemorrhage. PCV is more commonly seen in Asian and African or African American populations, while it is less frequent in Caucasians.
The incidence and prevalence of AMD increase significantly with age. Early AMD rises from about 3.9% in individuals aged 43–54 years to over 20% in those older than 75 years, while late AMD has a 5-year incidence of approximately 0.9%. Overall prevalence of AMD in adults over 40 years is around 9.2%. PCV prevalence varies widely, ranging from 4% to 14%, and may be significantly higher in certain populations, such as Japanese patients diagnosed with AMD. Risk factors for AMD include advancing age, family history, Caucasian race, smoking, hypertension, hyperlipidemia, obesity, and female gender. In contrast, PCV is more strongly associated with ethnicity and age.
Genetic factors play an important role in AMD, with associations identified in genes such as complement factor H (CFH), LOC387715, and HTRA1, with certain variants significantly increasing disease risk. PCV shares some genetic associations, particularly involving LOC387715 and HTRA1. The pathophysiology of AMD is multifactorial and includes degeneration of the retinal pigment epithelium (RPE), accumulation of photoreceptor debris forming drusen, reduced choroidal circulation leading to ischemia, and genetic susceptibility. In the exudative form, abnormal choroidal neovascular membranes develop beneath the retina or RPE, causing leakage and hemorrhage. In PCV, abnormalities in the inner choroidal vasculature result in polyp-like dilations and vascular networks that leak or bleed beneath the RPE.
Patients with AMD or PCV may present with central visual disturbances such as blurring, distortion (metamorphopsia), central scotomas, or may be asymptomatic in early stages. On examination, non-exudative AMD is characterized by drusen, pigmentary changes in the RPE, and eventual retinal thinning or geographic atrophy. Exudative AMD may show subretinal or intraretinal fluid, hemorrhage, lipid exudates, pigment epithelial detachment, or retinal pigment epithelial tears. PCV should be suspected in patients with exudative maculopathy, particularly in non-Caucasian individuals, those with peripapillary lesions, or cases with minimal drusen in the fellow eye.
Diagnosis relies heavily on imaging. Optical coherence tomography (OCT) is essential for identifying fluid, retinal thickening, and monitoring disease progression. Fluorescein angiography is used to identify and characterize choroidal neovascularization in AMD. Indocyanine green angiography is particularly useful in PCV for visualizing the characteristic polypoidal vascular lesions and branching networks. These imaging modalities are also critical in guiding treatment decisions and monitoring response to therapy.
Management of AMD depends on the stage and type of disease. For exudative AMD, intravitreal anti-vascular endothelial growth factor (anti-VEGF) agents such as bevacizumab and ranibizumab are the mainstay of treatment and have significantly improved visual outcomes. Additional therapies may include photodynamic therapy, thermal laser for selected cases, intravitreal steroids, or combination regimens in refractory cases. For non-exudative AMD, there is no curative treatment, but progression may be slowed with lifestyle modification and nutritional supplementation using AREDS formulations, which include vitamins C and E, zinc, beta-carotene, and copper. Risk factor modification, including smoking cessation and control of cardiovascular risk factors, is essential.
Management of PCV differs somewhat, with photodynamic therapy often playing a central role, particularly for subfoveal lesions. Anti-VEGF therapy is also used but may be less effective compared to its role in AMD, and combination therapy with anti-VEGF agents and photodynamic therapy has shown promising results. Referral to a retinal specialist is essential for both AMD and PCV to ensure appropriate diagnosis and management.
Patients require ongoing monitoring, including regular ophthalmologic evaluations and use of home Amsler grid testing to detect changes in vision. Low vision support may be necessary for those with significant visual impairment. Prognosis varies, with many patients maintaining functional vision with treatment, although both AMD and PCV can lead to progressive central vision loss. Despite this, these conditions do not affect overall lifespan or systemic health.
